Novartis, a major contributor to North Carolina’s reputation as “Vaccine Central,” is stepping up its game again. Not only is it planning to expand its $1 billion Holly Springs biomanufacturing campus with a $47 million addition starting next month, but the Swiss global pharmaceutical giant is also about to open a new R&D operation in Research Triangle Park.